Kiadis Pharma FY Net Loss Widens to 16.5 Million Euros
Friday, April 15, 2016
Kiadis Pharma BV FY net loss 16.5 million euros ($18.58 million) versus loss of 7.8 million year euros ago.
FY operating loss increased to 16.0 million euros in 2015 from a loss of 6.2 million euros in 2014.
Does not report any FY revenue, just like last year.
Says well positioned to begin Phase I/II clinical development with ATIR201 for thalassaemia.
Source : reuters.com
